奥沙米特治疗慢性荨麻疹。一项双盲安慰剂对照试验。

Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial.

作者信息

Peremans W, Mertens R L, Morias J, Campaert H

出版信息

Dermatologica. 1981;162(1):42-50. doi: 10.1159/000250232.

Abstract

Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria. For 5 weeks patients received at random either 30 mg oxatomide b.i.d. or a placebo. Oxatomide significantly reduced not only the duration of the attacks but also the severity of erythema, lesions and itching. This lower level of suffering was clearly reflected by a diminished need for additional antiallergic medication. The overall response to treatment was rated excellent or good in 72% of the oxatomide-treated patients against only 23% of the controls which is a significant difference. Sleepiness was reported in 1 patient of each group.

摘要

在一项针对35名慢性荨麻疹患者的双盲研究中对奥沙米特进行了评估。在5周的时间里，患者随机接受每日两次30毫克奥沙米特或安慰剂治疗。奥沙米特不仅显著缩短了发作时长，还减轻了红斑、皮损和瘙痒的严重程度。这种较低的痛苦程度明显体现在对额外抗过敏药物的需求减少上。在接受奥沙米特治疗的患者中，72%对治疗的总体反应评为优秀或良好，而对照组中这一比例仅为23%，两者存在显著差异。每组均有1名患者报告出现嗜睡症状。